Advances in therapeutic interventions targeting the vascular and lymphatic endothelium in inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 29, Issue 6, 2013, Pages 608-613

  D'Alessio, Silvia ^a   Tacconi, Carlotta ^a   Fiocchi, Claudio ^b,c   Danese, Silvio ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b Digestive Disease Institute   (Italy)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adhesion molecules; angiogenesis; endothelium; inflammatory bowel disease; lymphangiogenesis

Indexed keywords

CD18 ANTIGEN; ETROLIZUMAB; FIBROBLAST GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN A;

ANGIOGENESIS; CROHN DISEASE; ENDOTHELIUM CELL; ENTERITIS; INFLAMMATION; INFLAMMATORY INFILTRATE; LEUKOCYTE MIGRATION; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MEDIATOR RELEASE; PATHOGENESIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; ULCERATIVE COLITIS; UPREGULATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ENDOTHELIUM, LYMPHATIC; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; LYMPHANGIOGENESIS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84886094366     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328365d37c     Document Type: Review

References (74)

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 2006; 12:4807-4812. (Pubitemid 44323204)
2. Fiocchi C. Intestinal inflammation: a complex interplay of immune and nonimmune cell interactions. Am J Physiol 1997; 273 (4 Pt 1):G769-G775.
3. Fiocchi C. From immune activation to gut tissue injury: the pieces of the puzzle are coming together. Gastroenterology 1999; 117:1238-1241. (Pubitemid 29512685)
4. Alexander JS, Chaitanya GV, Grisham MB, Boktor M. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci 2010; 1207 (Suppl 1):E75-E85.
5. Chidlow JH Jr, Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol 2006; 169:2014-2030. (Pubitemid 351181962)
6. Chidlow JH Jr, Shukla D, Grisham MB, Kevil CG. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007; 293:G5-G18. (Pubitemid 47105158)
7. Esmon CT. Inflammation and thrombosis. J Thromb Haemost 2003; 1:1343-1348.
8. Panes J, Granger DN. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998; 114:1066-1090. (Pubitemid 28217575)
9. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immu-nobiology. Lancet 2007; 369:1627-1640. (Pubitemid 46722636)
10. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343:1020-1034.
11. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-621. (Pubitemid 43209108)
12. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110:673-687. (Pubitemid 35283958)
13. Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogen-esis of inflammatory bowel disease. Am J Physiol Heart Circ Physiol 2003; 285:H1791-H1796. (Pubitemid 37305919)
14. Granger DN. Cell adhesion and migration. II. Leukocyte-endothelial cell adhesion in the digestive system. Am J Physiol 1997; 273 (5 Pt 1): G982-G986. (Pubitemid 27508258)
15. Danese S, Semeraro S, Marini M, et al. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig Liver Dis 2005; 37:811-818. (Pubitemid 44356115)
16. Fiorino G, Correale C, Fries W, et al. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol 2010; 6:567-572.
17. Rivera-Nieves J, Gorfu G, Ley K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm Bowel Dis 2008; 14:1715-1735.
18. Stefanelli T, Malesci A, De La Rue SA, Danese S. Antiadhesion molecule therapies in inflammatory bowel disease: touch and go. Autoimmun Rev 2008; 7:364-369.
19. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151:97-110. (Pubitemid 27283962)
20. Rivera-Nieves J, Olson T, Bamias G, et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005; 174:2343-2352. (Pubitemid 40223984)
21. Danese S, Sans M, Scaldaferri F, et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176:2617-2624. (Pubitemid 43201714)
22. Danese S, Papa A, Saibeni S, et al. Inflammation and coagulation in inflammatory bowel disease: the clot thickens.AmJGastroenterol 2007; 102:174-186. (Pubitemid 46072059)
23. Danese S, Sans M, de la Motte C, et al. Angiogenesisasanovel component of inflammatory bowel disease pathogenesis. Gastroenterology 2006; 130: 2060-2073. (Pubitemid 43816964)
24. Pousa ID, Mate J, Gisbert JP. Angiogenesis in inflammatory bowel disease. Eur J Clin Investig 2008; 38:73-81. (Pubitemid 351143416)
25. Danese S, Sans M, Spencer DM, et al. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 2007; 56:855-862. (Pubitemid 46854204)
26. Koutroubakis IE, Tsiolakidou G, Karmiris K, Kouroumalis EA. Role of angiogen-esis in inflammatory bowel disease. Inflamm Bowel Dis 2006; 12:515-523.
27. Wakefield AJ, Sankey EA, Dhillon AP, et al. Granulomatous vasculitis in Crohn's disease. Gastroenterology 1991; 100 (5 Pt 1):1279-1287.
28. Ginnan R, Guikema BJ, Halligan KE, et al. Regulation of smooth muscle by inducible nitric oxide synthase and NADPH oxidase in vascular proliferative diseases. Free Radic Biol Med 2008; 44:1232-1245.
29. Ganta VC, Cromer W, Mills GL, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis 2010; 16:1029-1039.
30. Weidner N. Current pathologic methods for measuring intratumoral micro-vessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995; 36:169-180; Review.
31. Bagli E, Xagorari A, Papetropoulos A, et al. Angiogenesis in inflammation. Autoimmun Rev 2004; 3 (Suppl 1):S26.
32. Tolstanova G, Khomenko T, Deng X, et al. Neutralizing antivascular endothelial growth factor (VEGF) antibody reduces severity of experimental ulcerative colitis in rats: direct evidence for the pathogenic role of VEGF. J Pharmacol Exp Therapeut 2009; 328:749-757.
33. Morris GP, Beck PL, Herridge MS, et al. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96:795-803. (Pubitemid 19057602)
34. Peterson TC, Cleary CE, Shaw AM, et al. Therapeutic role for bismuth compounds in TNBS-induced colitis in the rat. Digest Dis Sci 2000; 45: 466-473. (Pubitemid 30171919)
35. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology 2009; 136:585-595; e5.
36. Kenet G, Wardi J, Avni Y, et al. Amelioration of experimental colitis by thalidomide. Isr Med Assoc J 2001; 3:644-648. (Pubitemid 34044156)
37. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000; 6:389-395. (Pubitemid 30208155)
38. Majno G. Chronic inflammation: links with angiogenesis and wound healing. Am J Pathol 1998; 153:1035-1039. (Pubitemid 28465827)
39. Carmeliet P. Angiogenesis in health and disease. Nature Med 2003; 9:653-660. (Pubitemid 36749213)
40. Cane G, Moal VL, Pages G, et al. Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli. PloS One 2007; 2:e1359.
41. Oshima T, Laroux FS, Coe LL, et al. Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function. Micro-vasc Res 2001; 61:130-143. (Pubitemid 32977762)
42. Siegmund B. Targeted therapies in inflammatory bowel disease. Dig Dis 2009; 27:465-469.
43. Kane SV, Horst S, Sandborn WJ, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012; 18:2203-2208.
44. Gordon FH, Hamilton MI, Donoghue S, et al. A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment Pharmacol Ther 2002; 16:699-705. (Pubitemid 34407517)
45. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013; 62:1122-1130.
46. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507. (Pubitemid 41007865)
47. Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370-1377.
48. Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19:1691-1699.
49. Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohn Colitis 2013; S1873-9946:00138-4.
50. Ito H, Kihara H, Andou A, et al. Oral treatment with novel alpha4 integrin blocker, AJM300, is efficacious in a rat model of DNBS-induced colitis. Gastroenterology 2005; 128:A200-A210.
51. Takazoe M, Watanabe M, Kawaguchi T, et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009; 136:A181-A190.
52. Sheremata WA, Vollmer TL, Stone LA, et al. A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. Neurology 1999; 52:1072-1074. (Pubitemid 29161624)
53. Linda H, von Heijne A, Major EO, et al. Progressive multifocal leukoence-phalopathy after natalizumab monotherapy. N Engl J Med 2009; 361:1081-1087.
54. Rutella S, Fiorino G, Vetrano S, et al. Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol 2011; 106:762-770.
55. Gardlik R, Bartonova A, Celec P. Therapeutic DNA vaccination and RNA interference in inflammatory bowel disease. Int J Mol Med 2013; 32:492-496.
56. Knod L, Donovan EC, Chernoguz A, et al. Vascular endothelial growth factor receptor-2 inhibition in experimental murine colitis. J Surg Res 2013; 184:101-107.
57. Adenis A, Vanseymortier L, Foissey D, Colombel JF. Bevacizumab and postponed suture leakages after surgery for ulcerative colitis and rectal cancer. Gut 2007; 56:734. (Pubitemid 46662946)
58. Hindryckx P, Waeytens A, Laukens D, et al. Absence of placental growth factor blocks dextran sodium sulfate-induced colonic mucosal angiogenesis, increases mucosal hypoxia and aggravates acute colonic injury. Lab Invest 2010; 90:566-576.
59. Loriot Y, Boudou-Rouquette P, Billemont B, et al. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 2008; 19:1975.
60. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438:946-953. (Pubitemid 43093960)
61. Saharinen P, Tammela T, Karkkainen MJ, Alitalo K. Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25:387-395. (Pubitemid 38780956)
62. Van Kruiningen HJ, Colombel JF. The forgotten role of lymphangitis in Crohn's disease. Gut 2008; 57:1-4.
63. Kalima TV. Experimental lymphatic obstruction in the ileum. Ann Chir Gynae-col Fenn 1970; 59:187-201.
64. Kalima TV, Collan Y. Intestinal villus in experimental lymphatic obstruction. Correlation of light and electron microscopic findings with clinical diseases. Scand J Gastroenterol 1970; 5:497-510.
65. Geleff S, Schoppmann SF, Oberhuber G. Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch 2003; 442:231-237. (Pubitemid 36399216)
66. Pedica F, Ligorio C, Tonelli P, et al. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch 2008; 452:57-63.
67. Rahier JF, De Beauce S, Dubuquoy L, et al. Increased lymphatic vessel density and lymphangiogenesis in inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34:533-543.
68. Fogt F, Pascha TL, Zhang PJ, et al. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int J Mol Med 2004; 13:211-214.
69. Wu TF, MacNaughton WK, von der Weid PY. Lymphatic vessel contractile activity and intestinal inflammation. Mem Inst Oswaldo Cruz 2005; 100 (Suppl 1):107-110. (Pubitemid 40685448)
70. Tonelli F, Giudici F, Liscia G. Is lymphatic status related to regression of inflammation in Crohn's disease? World J Gastrointest Surg 2012; 4:228-233.
71. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002; 82:673-700. (Pubitemid 34743335)
72. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005; 97:14-21.
73. D'Alessio S, Correale C, Arena V, et al. Stimulation of lymphatic function via VEGFR-3 as a novel therapy for chronic experimental intestinal inflammation. Gastroenterology 2012; 142:S84-S85.
74. Jurisic G, Sundberg JP, Detmar M. Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement. Inflamm Bowel Dis 2013; 19:1983-1989.